Table 3 Associations between adipokines and all-cause mortality and breast cancer specific mortality in breast cancer patients with repeated measurements.

From: Association of circulating leptin, adiponectin, and resistin concentrations with long-term breast cancer prognosis in a German patient cohort

N/events

All-cause mortalitya

Breast cancer mortalityb

Risk of recurrenceb

1,587/147

1,576/74

1,466/92

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Leptin continuous

0.98 (0.85, 1.12)

0.73

0.98 (0.80, 1.19)

0.81

1.05 (0.88, 1.25)

0.58

Baseline quintiles c (ng/ml)

 < 1.82

Reference

 

Reference

 

Reference

 

 < 3.47

0.99 (0.62, 1.59)

 

0.93 (0.46, 1.85)

 

0.60 (0.31, 1.14)

 

 < 5.98

0.82 (0.48, 1.40)

 

0.90 (0.42, 1.93)

 

1.20 (0.66, 2.18)

 

 < 10.66

1.10 (0.61, 1.98)

 

1.43 (0.63, 3.21)

 

0.72 (0.32, 1.59)

 

10.66 + 

1.43 (0.76, 2.71)

 

1.40 (0.53, 3.71)

 

0.90 (0.35, 2.28)

 

Adiponectin continuous

1.17 (0.95, 1.44)

0.15

1.18 (0.89, 1.59)

0.27

1.04 (0.80, 1.36)

0.78

Baseline quintiles c (mg/l)

 < 14.95

Reference

 

Reference

 

Reference

 

 < 21.26

1.95 (0.92, 4.12)

 

1.37 (0.44, 4.33)

 

1.28 (0.56, 2.92)

 

 < 28.14

1.80 (0.86, 3.75)

 

2.53 (0.90, 7.12)

 

1.00 (0.42, 2.39)

 

 < 39.31

1.31 (0.62, 2.77)

 

1.84 (0.66, 5.12)

 

1.04 (0.46, 2.34)

 

39.31 + 

1.84 (0.91, 3.70)

 

1.74 (0.64, 4.73)

 

1.20 (0.55, 2.61)

 

Resistin continuous

1.11 (0.93, 1.33)

0.26

1.23 (0.94, 1.60)

0.13

1.13 (0.88, 1.45)

0.34

Baseline quintiles c (ng/ml)

 < 7.87

Reference

 

Reference

 

Reference

 

 < 12.57

1.22 (0.47, 3.20)

 

0.40 (0.07, 2.41)

 

1.08 (0.32, 3.69)

 

 < 19.09

1.60 (0.64, 4.01)

 

1.67 (0.44, 6.19)

 

1.78 (0.56, 5.70)

 

 < 31.39

1.81 (0.74, 4.43)

 

1.26 (0.34, 4.64)

 

1.03 (0.31, 3.40)

 

31.39 + 

1.81 (0.75, 4.36)

 

1.87 (0.54, 6.51)

 

1.51 (0.48, 4.72)

 
  1. aModels were adjusted for the other adipokines, BMI, region, age at diagnosis, time between diagnosis and first blood draw, timing of blood draw in relation to chemotherapy, tumor size, nodal status, metastasis, grading, combined estrogen/progesterone receptor status, previous tumors, MHT use, leisure time PA at age 50 (quintiles of MET x h/wk), mode of detection by imaging (yes/no), alcohol consumption smoking, CVD, and diabetes.
  2. bModels were adjusted for the other adipokines, BMI, region, age at diagnosis, time between diagnosis and first blood draw, timing of blood draw in relation to chemotherapy, tumor size, nodal status, metastasis, grading, combined estrogen/progesterone receptor status, previous tumors, MHT use, leisure time PA at age 50 (quintiles of MET x h/wk), mode of detection by imaging (yes/no), combined Her2 receptor status/trastuzumab use, radiotherapy, tamoxifen and/or aromatase inhibitor.
  3. cQuintiles were derived from baseline measurements. FU measurements were categorized into respective baseline quintiles.
Back to article page